Drug intelligence / Profile preview

vorinostat + melphalan + prednisone

Development stage: Unknown
Lead developer: Tiziana Marangon
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Vorinostat + melphalan + prednisone (ZMP) is a combination regimen investigated for the treatment of relapsed or refractory multiple myeloma. Vorinostat (Zolinza) is a small molecule inhibitor of Class I and II histone deacetylases (HDAC), which induces cell cycle arrest and apoptosis in malignant cells. Melphalan is a nitrogen mustard alkylating agent that causes DNA cross-linking, and prednisone is a synthetic corticosteroid with anti-inflammatory and immunosuppressive properties. This specific combination was evaluated in a Phase I/II clinical trial (NCT00857324) led by Tiziana Marangon at the University of Turin to determine if the synergistic effects of HDAC inhibition could enhance the efficacy of the standard melphalan-prednisone (MP) backbone in advanced myeloma patients.

Brand names: Zolinza
Other names: vorinostat-melphalan-prednisoneSAHA + melphalan + prednisonesuberoylanilide hydroxamic acid + melphalan + prednisone

Targets

HDAC6 (Histone deacetylase 6)HDAC1 (Histone Deacetylase 1)GR (Glucocorticoid receptor)DNA

Beyond the preview

Go deeper on vorinostat + melphalan + prednisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vorinostat + melphalan + prednisone.

Explore the full profile